B-cell receptor specific for Human Papillomavirus L1 conformational epitopes (HPV L1-specific BCR)

The B-cell receptor (BCR) specific for Human Papillomavirus (HPV) L1 conformational epitopes is a membrane-bound immunoglobulin that plays a critical role in the adaptive immune response against HPV (Schiller & Lowy, 2012, Nature Reviews Microbiology). The HPV L1 protein is the major capsid protein of the virus and spontaneously assembles into virus-like particles (VLPs) that display complex, three-dimensional conformational epitopes (Buck et al., 2013, Journal of Virology). These epitopes are the primary targets for neutralizing antibodies, which are essential for preventing HPV infection (Kirnbauer et al., 1992, PNAS). When these BCRs encounter L1 VLPs—either from natural infection or via vaccination—they initiate B-cell activation, leading to the generation of long-lived plasma cells and memory B cells (Bachmann & Jennings, 2010, Nature Reviews Immunology). This process is the fundamental mechanism behind the efficacy of HPV vaccines like Gardasil and Cervarix (Harper & DeMars, 2017, Gynecologic Oncology). By inducing high titers of neutralizing antibodies, the immune system can block the virus from entering the basal epithelium, thereby preventing the development of cervical, anal, and oropharyngeal cancers (CDC, 2021). Therapeutic strategies focusing on this receptor aim to maximize the breadth and longevity of the humoral immune response against high-risk HPV genotypes (Stanley, 2010, Vaccine).

Other names

HPV L1-specific B-cell receptorAnti-HPV L1 BCRHuman Papillomavirus L1-specific B-cell receptorL1-specific BCRHPV L1-specific immunoglobulin

Vaccine-derived virus-like particles (VLPs) mimic the structure of the HPV virion, presenting high-density conformational epitopes that cross-link B-cell receptors (BCRs) on specific B-lymphocytes (Bachmann & Jennings, 2010, Nature Reviews Immunology). This interaction triggers signal transduction, B-cell activation, and the subsequent production of high-titer neutralizing antibodies that prevent viral entry into host cells (Schiller & Lowy, 2012, Nature Reviews Microbiology).